NMNikki McArthur

Nikki McArthur

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Nikki McArthur has a total of 41 co-authors. Here are the top co-authors by number of shared publications:

  • Nemil N. Bhatt

    Mitchell Center for Neurodegenerative Disease, University of Texas Medical Branch, Galveston, USA

    4 shared publications
  • Alec A. Desai

    Department of Chemical Engineering, University of Michigan, Ann Arbor, USA

    3 shared publications
  • Balaji M. Rao

    Department of Chemical and Biomolecular Engineering, North Carolina State University, Raleigh, NC 27695, USA

    3 shared publications
  • Cynthia Jerez

    Mitchell Center for Neurodegenerative Disease, University of Texas Medical Branch, Galveston, USA

    3 shared publications
  • Jennifer M. Zupancic

    Department of Chemical Engineering, University of Michigan, Ann Arbor, USA

    3 shared publications
  • Ravi S. Kane

    School of Chemical & Biomolecular Engineering Georgia Institute of Technology Atlanta Georgia USA

    3 shared publications

Latest Publications

  • Facile generation of drug-like conformational antibodies specific for amyloid fibrils

    by Alec A. Desai, Jennifer M. Zupancic, Hanna Trzeciakiewicz, Julia E. Gerson, Kelly N. DuBois, Mary E. Skinner, Lisa M. Sharkey, Nikki McArthur, Sean P. Ferris, Nemil N. Bhatt, et al.

    Antibodies that recognize insoluble antigens, such as amyloid fibrils associated with neurodegenerative disorders, are important for research, diagnostic and therapeutic applications. However, these types of antibodies are difficult to generate, typically require animal immunization and also commonly require humanization in the case of therapeutic applications. Here we report a methodology for generating high-quality, fully human, conformation-specific antibodies against amyloid fibrils using a published human nonimmune library, yeast-surface display and quantitative fluorescence-activated cell sorting. Notably, this approach enables the isolation of conformation-specific antibodies against tau fibrils (Alzheimer’s disease) and α-synuclein fibrils (Parkinson’s disease) with combinations of high affinity, high conformational specificity and, in some cases, low off-target binding that rival or exceed those of clinical-stage antibodies specific for tau (zagotenemab) and α-synuclein (cinpanemab). This approach is expected to simplify the generation of conformation-specific antibodies against diverse protein aggregates and other insoluble antigens.


  • Open Access

    Generation of nanobodies with conformational specificity for tau oligomers that recognize tau aggregates from human Alzheimer's disease samples

    by Nikki McArthur, Jay D. Squire, Ogechukwu J. Onyeachonam, Nemil N. Bhatt, Cynthia Jerez, Abigail L. Holberton, Peter M. Tessier, Levi B. Wood, Rakez Kayed, Ravi S. Kane

    Nanobodies OT2.4 and OT2.6 bind with conformational specificity to recombinant tau oligomers over monomeric and fibrillar tau. These nanobodies recognize tau oligomers present in brain samples from Alzheimer's disease patients.


  • Open Access

    Development of a pan‐tau multivalent nanobody that binds tau aggregation motifs and recognizes pathological tau aggregates

    by Nikki McArthur, Bokyung Kang, Felix G. Rivera Moctezuma, Akber T. Shaikh, Kathryn Loeffler, Nemil N. Bhatt, Madison Kidd, Jennifer M. Zupancic, Alec A. Desai, Naima Djeddar, et al.

    Alzheimer's disease and other tauopathies are characterized by the misfolding and aggregation of the tau protein into oligomeric and fibrillar structures. Antibodies against tau play an increasingly important role in studying these neurodegenerative diseases and the generation of tools to diagnose and treat them. The development of antibodies that recognize tau protein aggregates, however, is hindered by complex immunization and antibody selection strategies and limitations to antigen presentation. Here, we have taken a facile approach to identify single‐domain antibodies, or nanobodies, that bind to many forms of tau by screening a synthetic yeast surface display nanobody library against monomeric tau and creating multivalent versions of our lead nanobody, MT3.1, to increase its avidity for tau aggregates. We demonstrate that MT3.1 binds to tau monomer, oligomers, and fibrils, as well as pathogenic tau from a tauopathy mouse model, despite being identified through screens against monomeric tau. Through epitope mapping, we discovered binding epitopes of MT3.1 contain the key motif VQIXXK which drives tau aggregation. We show that our bivalent and tetravalent versions of MT3.1 have greatly improved binding ability to tau oligomers and fibrils compared to monovalent MT3.1. Our results demonstrate the utility of our nanobody screening and multivalent design approach in developing nanobodies that bind amyloidogenic protein aggregates. This approach can be extended to the generation of multivalent nanobodies that target other amyloid proteins and has the potential to advance the research and treatment of neurodegenerative diseases.


  • Open Access

    Flow cytometric isolation of drug-like conformational antibodies specific for amyloid fibrils

    by Alec A. Desai, Jennifer M. Zupancic, Hanna Trzeciakiewicz, Julia E. Gerson, Kelly N. DuBois, Mary E. Skinner, Lisa M. Sharkey, Nikki McArthur, Sean P. Ferris, Nemil N. Bhatt, et al.

    Antibodies that recognize specific protein conformational states are broadly important for research, diagnostic and therapeutic applications, yet they are difficult to generate in a predictable and systematic manner using either immunization or in vitro antibody display methods. This problem is particularly severe for conformational antibodies that recognize insoluble antigens such as amyloid fibrils associated with many neurodegenerative disorders. Here we report a quantitative fluorescence-activated cell sorting (FACS) method for directly selecting high-quality conformational antibodies against different types of insoluble (amyloid fibril) antigens using a single, off-the-shelf human library. Our approach uses quantum dots functionalized with antibodies to capture insoluble antigens, and the resulting quantum dot conjugates are used in a similar manner as conventional soluble antigens for multi-parameter FACS selections. Notably, we find that this approach is robust for isolating high-quality conformational antibodies against tau and α-synuclein fibrils from the same human library with combinations of high affinity, high conformational specificity and, in some cases, low off-target binding that rival or exceed those of clinical-stage antibodies specific for tau (zagotenemab) and α-synuclein (cinpanemab). This approach is expected to enable conformational antibody selection and engineering against diverse types of protein aggregates and other insoluble antigens (e.g., membrane proteins) that are compatible with presentation on the surface of antibody-functionalized quantum dots.


  • Open Access

    Experimental and Analytical Framework for “Mix-and-Read” Assays Based on Split Luciferase

    by Nikki McArthur, Carlos Cruz-Teran, Apoorva Thatavarty, Gregory T. Reeves, Balaji M. Rao

    The use of immunodetection assays including the widely used enzyme-linked immunosorbent assay (ELISA) in applications such as point-of-care detection is often limited by the need for protein immobilization and multiple binding and washing steps. Here, we describe an experimental and analytical framework for the development of simple and modular "mix-and-read" enzymatic complementation assays based on split luciferase that enable sensitive detection and quantification of analytes in solution. In this assay, two engineered protein binders targeting non -overlapping epitopes on the target analyte were each fused to nonactive fragments of luciferase to create biosensor probes. Binding proteins to two model targets, lysozyme and Sso6904, were isolated from a combinatorial library of Sso7d mutants using yeast surface display. In the presence of the analyte, probes were brought into close proximity, reconstituting enzymatic activity of luciferase and enabling detection of low picomolar concentrations of the analyte by chemiluminescence. Subsequently, we constructed an equilibrium binding model that relates binding affinities of the binding proteins for the target, assay parameters such as the concentrations of probes used, and assay performance (limit of detection and concentration range over which the target can be quantified). Overall, our experimental and analytical framework provides the foundation for the development of split luciferase assays for detection and quantification of various targets.


  • Open Access

    Experimental and analytical framework for “mix-and-read” assays based on split luciferase

    by Nikki McArthur, Carlos Cruz-Teran, Apoorva Thatavarty, Gregory T. Reeves, Balaji M. Rao

    The use of immunodetection assays including the widely used enzyme-linked immunosorbent assay (ELISA) in applications such as point-of-care detection is often limited by the need for protein immobilization and multiple binding and washing steps. Here, we describe an experimental and analytical framework for the development of simple and modular “mix-and-read” enzymatic complementation assays based on split luciferase that enable sensitive detection and quantification of analytes in solution. In this assay, two engineered protein binders targeting non-overlapping epitopes on the target analyte were each fused to non-active fragments of luciferase to create biosensor probes. Binding proteins to two model targets, lysozyme and Sso6904, were isolated from a combinatorial library of Sso7d mutants using yeast surface display. In the presence of the analyte, probes were brought into close proximity, reconstituting enzymatic activity of luciferase and enabling detection of low picomolar concentrations of the analyte by chemiluminescence. Subsequently, we constructed an equilibrium binding model that relates binding affinities of the binding proteins for the target, assay parameters such as the concentrations of probes used, and assay performance (limit of detection and concentration range over which the target can be quantified). Overall, our experimental and analytical framework provide the foundation for the development of split luciferase assays for detection and quantification of various targets.

  • An Engineered Sso7d Variant Enables Efficient Magnetization of Yeast Cells

    by Carlos A. Cruz-Teran, Kaitlyn Bacon, Nikki McArthur, Balaji M. Rao

    Magnetization using cheap and minimally toxic materials, such as iron oxide nanoparticles can enable easy separation of cells from culture medium and is relevant to several industrial applications. Here, we show that cell surface expression of a mutant protein that binds iron oxide can enable efficient magnetization of yeast cells. We screened a combinatorial library of mutants derived from the Sso7d protein scaffold to isolate proteins that exhibit preferential binding to iron oxide. One of the isolated mutants, SsoFe2, was chosen for further characterization. Yeast cells expressing SsoFe2 as fusions to a cell wall protein—but not other Sso7d mutants with similar overall protein charge or amino acid composition—preferentially bind iron oxide when present in a solution with high protein concentration and in the presence of 1000-fold excess of competitor yeast cells. Moreover, coexpression of cell surface SsoFe2 enables efficient magnetic capture and separation of yeast cells expressing an enzyme (glucose oxidase) on the cell surface from yeast culture medium, and solutions with high protein concentration or containing other metal oxides. Therefore, SsoFe2-enabled magnetization can enable a range of industrial and biotechnology applications, where easy separation of cells or organelles from complex media is desirable.